Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Relative Bioavailability of Tablet Formulation of Dabigatran Etexilate With and Without Co-administration of Rabeprazole in Healthy Male Subjects (an Open-label, Single-dose, Two-period, Single-arm Study)

Trial Profile

Relative Bioavailability of Tablet Formulation of Dabigatran Etexilate With and Without Co-administration of Rabeprazole in Healthy Male Subjects (an Open-label, Single-dose, Two-period, Single-arm Study)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Rabeprazole
  • Indications Cardiomyopathies; Cardiovascular disorders; Deep vein thrombosis; Embolism; Gastrointestinal haemorrhage; Pulmonary embolism; Stroke; Vascular disorders; Venous thromboembolism
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 30 Oct 2019 Results investigating bioequivalence (BE) of the novel DE tablet versus the commercial DE capsule and DE bioavailability (BA) under pretreatment with the PPI rabeprazole and assessing the effect of elevated pH on exposure to dabigatran using two trials (NCT03070171, and NCT03143166) published in the American Journal of Cardiovascular Drugs
    • 16 Aug 2017 Status changed from recruiting to completed.
    • 01 Jun 2017 Status changed from not yet recruiting to recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top